Prospects for the Use of Universal Serum Substitute eBS for Cultivation of Stable Human Cell Lines
Cell and Tissue Biology,
Journal Year:
2025,
Volume and Issue:
19(2), P. 113 - 124
Published: Feb. 10, 2025
Language: Английский
Tumor tissue samples collection for scientific research in morphology and molecular oncology
O. R. Khabarov,
No information about this author
B. D. Seferov,
No information about this author
K. A. Aliev
No information about this author
et al.
Research and Practical Medicine Journal,
Journal Year:
2024,
Volume and Issue:
11(1), P. 29 - 39
Published: Feb. 19, 2024
Purpose
of
the
study
.
Is
to
describe
experience
creating
a
collection
biological
images
tumor
tissues
and
biomaterials,
which
are
control
samples,
for
scientific
research
in
morphology
molecular
oncology.
Materials
methods.
We
studied
markers
cell
cycle
regulation,
apoptosis,
oncogenesis
angiogenesis,
expression
proteins
that
regulate
inflammation
infiltrate
cells
biocollections
verified
tumors
common
localizations:
e.
g.
thyroid
cancer,
colorectal
breast
prostate
adenocarcinoma,
endometrioid
adenocarcinoma.
Also,
tissue
fragments
with
normal
structure
or
non-tumor
pathology
(autoimmune
thyroiditis,
adenomatous
thyrotoxic
goiter,
benign
formations
colon,
fibrocystic
disease
mammary
glands,
prostatic
hyperplasia,
endometrial
hyperplasia)
were
used
as
samples
comparison
groups.
The
total
number
is
n
=
7000.
Results.
It
reasonable
gather
pathomorphological
laboratory
according
profile
medical
institutions,
has
sufficient
volume
incoming
target
material
specialized
morphologists
verify
given
localization.
necessary
consider
regional
ethnic
specifics
population,
determines
sampling
mutational
load.
must
initiate
an
addition
informed
consent
patients
about
possibility
conducting
morphological
genetic
studies
purposes
publishing
their
results
depersonalized
form
development
new
elaborations,
when
signing
contracts
legal
entities
individuals
serving
within
institution.
When
working
biocollections,
it
having
registers
biomaterials
disorder
groups
main
localizations
downloading
by
year
from
accessible
information
system,
external
factors
affecting
database
(changes
clinical
recommendations
classifications,
population
served,
pandemics
other
significant
events).
standard
preanalytical
stage,
data
collection,
protocols
analytical
evaluation,
utilization
capabilities
reagents
tasks
modeling
experiments
on
animals
crucial.
Conclusion.
formed
biocollection
made
possible
carry
out
initiative
funded
domestic
international
projects
at
request
clinicians
fundamental
researchers,
well
improve
quality
standards
oncology
diagnostics.
Biobanking
makes
pathological
archive
more
review
use,
significantly
expanding
its
practical
potential.
Scientific
do
not
conflict
can
be
same
laboratory.
Language: Английский
Role of biobanking in the development of personalized medicine in Russia and the world
CARDIOVASCULAR THERAPY AND PREVENTION,
Journal Year:
2024,
Volume and Issue:
23(11), P. 4214 - 4214
Published: Dec. 28, 2024
To
implement
a
modern
personalized
approach
in
practical
healthcare,
the
latest
biomedical
technologies
should
be
developed
and
genetic
research
performed.
The
analysis
of
substantial
quantity
data
is
essential
for
investigation
prevalence
risk
factors
various
diseases,
drug
resistance
genes,
development
panels
to
determine
individual
pathologies,
as
well
creation
scores.
review
demonstrates
through
use
illustrative
examples
that
contemporary
biobanks
have
become
vital
component
field
genetics
research,
both
Russia
globally.
These
specialized
institutions
are
capable
accumulating,
storing,
utilizing
biological
samples
related
data,
which
advancing
research.
collected
associated
clinical
information
form
basis
large-scale
studies
conducted
different
countries.
efficacy
advancements,
such
early
diagnosis
contingent
upon
number
biobanks,
establishment
collaborative
networks
among
them,
capacity
leverage
digital
platforms
uniting
diverse
databases.
Biobanks
biobanking
emerged
foundation
advancement
medicine.
Language: Английский
Creation of a plasma collection for the search of diagnostic biomarkers of glial tumors
CARDIOVASCULAR THERAPY AND PREVENTION,
Journal Year:
2024,
Volume and Issue:
23(11), P. 4171 - 4171
Published: Dec. 30, 2024
Aim
.
To
create
a
collection
of
plasma
samples
patients
with
brain
tumors
(BTs)
for
the
development
diagnostic
microRNA
(ribonucleic
acid)
panel
glial
tumors.
Material
and
methods
Plasma
benign
malignant
BTs
were
obtained
by
double
centrifugation
whole
blood
then
frozen
at
-75оС.Fifty-nine
RNA
isolated
from
analyzed
next-generation
sequencing
(NGS).
Results
Currently,
biobank
contains
339
primary
secondary
10
control
group
individuals
(698
—
2
aliquots
per
individual),
including
143
men
206
women.
The
age
ranged
19
to
91
years
(median
56
years).
Primary
(41%)
included
two
following
groups:
(33,7%)
(66,3%).
Meningiomas
constituted
bulk
(91%)
BTs.
Among
tumors,
glioblastomas
(46,7%)
astrocytomas
(41,6%)
prevailed,
while
oligodendrogliomas
ependymomas
accounted
only
9,1
2,5%,
respectively.
Secondary
(59%)
are
represented
recurrent
(92,5%)
metastatic
(7,5%)
lung
cancer
(71,4%)
breast
(28.6%).
A
protocol
preparation
liquid
biopsy
was
implemented,
which
made
it
possible
obtain
high-quality
deoxyribonucleic
acid
libraries
selected
profiling
platform.
Conclusion
creation
sample
is
basis
searching
circulating
biomarkers
Language: Английский